Tirzepatide and semaglutide were associated with larger QALY gains (incremental gains of 0.35 and 0.25 over lifestyle ...

Depression risk for patients receiving GLP-1 RA was slightly higher than those receiving SGLT-2i and lower than those receiving DPP-4i.

Patients who continued Ozempic through total joint arthroplasty had higher risk for complications compared with those who stopped GLP-1RAs before surgery.

Consolidated revenues increased 43% year-over-year to $64.3 million with telehealth revenue up 60%Adjusted EBITDA increased 78% to $9.0 millionTelehealth adjusted EBITDA increased 396% to $5.9 million ...

Also: Warnings from the stock and real-estate markets; Eli Lilly’s success; a mixed response to Nvidia; and how cuts to Social Security and other government agencies can affect you or loved ones.

The above chart underscores the current buzz that ... And those gains followed a return of 31.5% in 2024, on the success of the company's GLP-1 medications for Type 2 diabetes and weight loss.

Now, with the commissioning of our ECO Synthesis™ Innovation Lab we are ready to convert ongoing collaborations ... providing analytical services and GLP-grade siRNA material through the ECO ...

I expect price sensitive consumers to flood the market for compounded GLP-1 drugs before the 60-day FDA grace period for semaglutide compounders. HIMS projects $725M in GLP-1 weight loss revenue ...

With the rising global obesity epidemic and the increasing demand for effective weight-loss treatments, the biopharma industry faces mounting pressure to revolutionize GLP-1 manufacturing to meet ...

I will be particularly interested in the company’s plan to attract and retain weight loss subscribers in the coming absence of popular GLP-1 compounds.

This indicates that GLP-1 receptor agonists lead to greater reduction in overall body fat than that in muscle mass, resulting in an overall body fat percentage decrease of around 4.5%.